New York, September 17, 2013 -- Moody's Investors Service commented the upsized term loan of Auxilium Pharmaceuticals, Inc. ("Auxilium") to $275 million from $225 million is credit negative. There is currently no effect on Auxilium's ratings including the B2 Corporate Family Rating or the Ba2 senior secured bank credit facility rating. Proceeds of the upsized term loan are expected to be used for general corporate purposes which may include acquisitions.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.